SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Genmab Combination Shows 28.2-Month Median Survival in Phase 2 Trial

Genmab said its petosemtamab-pembrolizumab combination achieved median survival of 28.2 months in a Phase 2 head and neck cancer trial.

Related stories